A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer.

ABSTRACT:

Background

Breast cancer has an unacceptably high recurrence rate when any residual disease is found following neoadjuvant treatment of high-risk disease. Based on clinical data suggesting an adjuvant role for epigenetic modifying agents in breast cancer and preclinical data suggesting synergistic activity of entinostat combined with capecitabine, we conducted a phase I, open-label study of these agents in metastatic breast cancer (MBC). Both agents have published doses for use in combination therapy, but the agents had not previously been combined with each other in a human trial.

Methods

A multisite phase I dose escalation study was performed at two academic centers. Patients with pretreated, HER2-negative MBC, and measurable disease were enrolled. Dual dose escalation was

SUBMITTER: Millard T 

PROVIDER: S-EPMC10866629 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature